secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001171843-22-001774
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC
--------------------------------------------------------------------------------

- Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).
- Full year 2021 net loss $43.2M vs $6.0M in 2020; R&D expenses $29.1M down from $31.8M.
- Cash, equivalents and securities $69.5M at Dec 31, 2021, up from $44.3M; FY2022 cash burn guidance $34-36M.
- Plans randomized Phase 2 trial of mupadolimab plus chemo in front-line NSCLC (150 patients).
- Plans Phase 2 trial of ciforadenant plus ipilimumab/nivolumab in front-line RCC with Kidney Cancer Consortium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/0001171843-22-001774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/f8k_031022.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-001774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer